Previous reports have suggested that the ATP-binding cassette protein ABCG2 (BCRP, MXR) is associated with drug resistance in acute myeloid leukemia (AML). The aims of this study were to determine the level of ABCG2 mRNA expression necessary to produce drug resistance and to define the ABCG2 levels in normal bone marrow (BM), peripheral blood (PB), cord blood (CB), and adult AML blast cell populations. First, using transduced clonal cell lines expressing varying levels of ABCG2, we found that ABCG2 expression conferred resistance to mitoxantrone and topotecan, but not idarubicin. Next, we developed a real-time RT-PCR assay for measuring ABCG2 mRNA expression levels in clinical samples. Normal BM and PB contained low levels of ABCG2 mRNA, while higher levels were measured in CB mononuclear cells, CD34+, and Ac133+ populations, consistent with the known stem cell enrichment in these populations. Next, we studied the ABCG2 mRNA levels in 40 specimens from newly diagnosed adult AML patients. Only 7 % of these samples contained ABCG2 mRNA levels within the range of our drug resistant clone, although another 78 % were higher than normal blood and bone marrow. Flow cytometry revealed very small subpopulations of ABCG2-expressing cells in the cases we examined. Our data suggest that high levels of ABCG2 mRNA expression in adult AML blast specimens are relatively uncommon, and that ABCG2 expression may be limited to a small cell subpopulation in some cases.
Introduction
Drug resistance is a frequently encountered phenomenon contributing to treatment failure in acute leukemia. Several members of the ATP binding cassette (ABC) family of transmembrane transporters have been associated with drug resistance in AML, including Pglycoprotein 1, 2 , encoded by the multidrug resistance gene, MDR1, and the multidrug resistance protein, MRP1 3 . Several studies have suggested that other transporters may be responsible for the multidrug resistance phenotype in some AML cases. Leith et al showed that 18% of adult AML specimens had drug efflux activity, which was not associated with MDR1 or MRP1 expression, suggesting the presence of a previously unidentified transporter 4 .
The transporter ABCG2, also designated BCRP and MXR, was recently described as a cause of the multidrug resistance phenotype 5 . ABCG2 mRNA expression was identified in approximately one third of cases of adult AML by semi-quantitative RT-PCR 6 . Another study detected ABCG2 protein expression in 27 % of cases by flow cytometry 7 . However, it is unclear if the ABCG2 mRNA expression measured in these samples was physiologically significant, or due to contamination from normal hematopoietic cells in low expressing cases.
Because ABCG2 expression has subsequently been demonstrated in several types of normal hematopoietic cells, including erythroid progenitors, natural killer cells, and primitive stem cells 8, 9 , expression in AML blast samples could be due to contamination from normal hematopoietic cells.
For personal use only. on . by guest www.bloodjournal.org From 4 The substrate profile of ABCG2 includes the antineoplastic drugs mitoxantrone and topotecan 10 . Mitoxantrone is commonly used in AML treatment, suggesting that ABCG2
could play an important role in drug resistance in this disease. Idarubicin is another anthracycline drug that is sometimes used in the treatment of AML, and it has not been known whether ABCG2 expression can confer resistance to idarubicin.
ABCG2 is known to efflux the fluorescent dye, Hoescht 33342, but not rhodamine 123 8, 11 .
This dye efflux activity can be used to identify hematopoietic stem cells using the "side population" (SP) assay 12, 13 , and previous studies have identified ABCG2 expression as a molecular determinant of the side population (SP) phenotype 8, 9 . This finding may be important in AML for several reasons. First, several investigators have found the frequent presence of SP cells in bone marrow from AML patients 14, 15 . While in both studies the SP cells were usually leukemic, Feuring-Buske et al demonstrated that specimens from most AML patients contained both leukemic and non-leukemic SP cells 15 . Interestingly, these SP cells frequently did not express MDR1 and were capable of multilineage NOD/SCID engraftment. These studies provide further evidence that a transporter such as ABCG2 may be expressed in stem cells of both normal and leukemic origin.
To assess ABCG2 expression in AML patient samples, we developed clonal human AML cell lines by transduction with a retroviral vector containing the ABCG2 cDNA. Using these clonal cell lines, we identified a low-expressing clone, referred to as clone 3.3 , that has readily detectable levels of ABCG2 mRNA by Real-Time RT-PCR analysis but very low levels of protein expression and no drug resistance. Another clone (6.2), with ABCG2 mRNA
For personal use only. on . by guest www.bloodjournal.org From 5 expression much higher than clone 3.3, demonstrated relatively high levels of protein expression by monoclonal antibody labeling, and mitoxantrone efflux assays. Resistance to several relevant cytotoxic drugs was then measured in these cell lines to develop a correlation between ABCG2 mRNA levels and functional drug resistance. The mRNA levels in these reference cell lines were also compared to those seen in normal hematopoietic cell populations and in 40 samples from adult AML patients. In several cases, blast cell populations were studied for ABCG2 protein expression using a monoclonal antibody we have recently generated. These expression and functional studies further clarify the role of ABCG2 expression in AML.
Materials and methods

Preparation of ABCG2-transduced clonal AML cell lines
OCI/AML3 cells 16 were grown in DMEM with 10 % fetal bovine serum. Derivation of the human ABCG2 expression vector, HaABCG2, and the subsequent transfection of an ecotropic producer cell line, has been previously described 8 . The amphotropic packaging line, PA317, was transduced with supernatant from the producer cells. Transduced PA317 cells were sorted to 100 % purity by flow cytometry for Hoescht 33342 efflux. Next, 8 x 10 6 irradiated PA317 / HaABCG2 cells were cultured in 9 mL of DMEM with 10 % fetal bovine serum (FBS), with the addition of 10 µL polybrene (Sigma, St. Louis, Missouri). 5.0 x 10 5 OCI-AML3 cells were added to the adherent producer cells for coculture. Nonadherent AML cells were then transferred to fresh plates of producer cells at daily intervals for four days.
Transduced OCI-AML3 / HaABCG2 cells were sorted based on Hoechst 33342 efflux, using 
Drug efflux assays
OCI-AML3 cell clones were used to study mitoxantrone efflux, as previously described 16 .
Briefly, 5 x 10 5 cells were harvested from suspension culture and washed in 3 mL phosphate buffered saline (PBS). Cells were then centrifuged for 5 minutes at 1500 RPM, and resuspended in 500 µL of DMEM with 10 % FBS containing 2 µg/mL mitoxantrone For personal use only. on . by guest www.bloodjournal.org From 8 CD34 and Ac133 cell enrichments were performed on mobilized peripheral blood leukapheresis products using the CliniMACS instrument (CS2 CE/UL, Miltenyi Biotec, Gladbach, Germany) and CD34 and Ac133 CliniMACS reagents and using the manufacturer's protocols. RNA was extracted using RNA STAT-60. 
SP analyses and antibody-mediated inhibition of efflux
AML blast samples
Northern analysis
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Northern analysis was performed as previously described 17 . Full-length ABCG2 cDNA probe was prepared by restriction digest of the pHaABCG2 plasmid with the enzymes NcoI and SacII (Promega, Madison, WI). The probe was radiolabeled with dCTP 32 using the NEBlot Kit according to the manufacturer's instructions (New England BioLabs, Beverly, Massachusetts), and hybridized at 42°C for 12 hours.
ABCG2 expression was normalized to Actin expression, using a Actin probe. Northern blots were analyzed using the Storm phosphor imager system (Molecular Dynamics, Sunnyvale, California) with ImageQuaNT software (Molecular Dynamics) for signal quantification and background subtraction. 
Drug sensitivity assays
The parental OCI-AML3 cell line and ABCG2-transduced clones designated 3. Aqueous solution (Promega) was added to each well and incubated at 37°C for one hour.
Ultraviolet absorption was measured using a plate reader with a 492 nm filter and absorbance was measured at 650 nM. Results were calculated by subtracting the background absorbance obtained with plain medium from the absorbance of each experimental sample. Percentage viability was determined by dividing the absorbance of each sample by the absorbance of untreated wells. Results are expressed as the means of 6 replicate determinations, relative to the amount of viability detected in the untreated wells.
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Statistical methods
Statistics were calculated using GraphPad Prism , version 3.02 for Windows (GraphPad Software, San Diego, California). Normality of results distribution was analyzed using the KS test. Normal hematopoietic cell populations were compared using the two-tailed unpaired Student's T-test. Nonparametric data sets from leukemic patient samples were compared with the Mann-Whitney U test.
Results
Characterization of ABCG2 expressing AML cell lines
To develop cell line standards for ABCG2 mRNA expression, we prepared clonal AML cell lines based on the parental AML cell line, OCI-AML3 16 . These cells were transduced with the HaABCG2 retroviral vector 8 and single transduced cells were isolated using a single-cell sorter. Numerous clones were expanded and screened for ABCG2-mediated mitoxantrone efflux activity. Two individual clones, designated 3.3 and 6.2, were chosen for subsequent studies based on their respective low and high levels of efflux activity.
First, the clones were analyzed by flow cytometry for their capacity to efflux mitoxantrone.
The parental OCI-AML3 cells showed no intrinsic efflux capacity, clone 3.3 had a trace amount of efflux, and clone 6.2 displayed strong efflux activity (Fig. 1A) . The mean fluorescence intensities for the cell lines were 2298 for OCI-AML3, 2300 for clone 3.3, and We analyzed the presence of ABCG2 surface protein by flow cytometry using an anti-ABCG2 monoclonal antibody, 5D3, which recognizes an external epitope on the plasma membrane of living cells 8 . OCI-AML3 showed no significant labeling with the 5D3 antibody, clone 3.3
showed trace labeling, while clone 6.2 was strongly positive (Fig. 1A) . These results show that clone 6.2 expressed relatively high levels of ABCG2 protein, while clone 3. To further test for ABCG2 function in these cell lines, we performed side population (SP)
analyses by staining cells with Hoechst 33342 and using flow cytometry to quantify SP cell numbers. 13 We and others have previously shown that enforced ABCG2 expression confers the SP phenotype to transduced cells. 8, 9 As expected, clone 6.2 showed a large increase in SP cells relative to the untransduced AML3 parental line, and clone 3.3 showed a much smaller increase in SP cells over the parental line (Fig. 1B, top row) . The 5D3 monoclonal antibody 14 inhibits ABCG2 function, presumably by binding to an external epitope and preventing conformational changes in the transporter, and therefore provides a specific inhibitor assay for ABCG2 function. When cells were incubated with 5D3 prior to the SP analyses, both the 6.2 and 3.3 lines showed a marked decrease in SP cells (Fig. 1B, bottom row) . This result verifies the relative degrees of specific ABCG2 function in both the 6.2 and 3.3 cell lines. Figure 1B We also analyzed the capacity of clone 6.2 to efflux the anthracycline, idarubicin, a commonly used drug in AML induction chemotherapy. In contrast to the results seen with mitoxantrone, no significant efflux of idarubicin was detected (Fig. 1C) .
Figure 1A
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Figure 1C
To measure drug resistance of the two clones, we used a modified MTT assay, which measured cell viability following 96 hours of continuous drug incubation with mitoxantrone, topotecan, or idarubicin. We found that clone 6.2 was highly resistant to mitoxantrone and topotecan, but not idarubicin (Figures 2A-C) . In contrast, clone 3.3 showed no significant resistance to any of the agents. These results demonstrate that: 1) the level of ABCG2 expression in clone 6.2 confers significant resistance to mitoxantrone and topotecan, 2) the low level of ABCG2 expression in clone 3.3 does not confer drug resistance in these assays, and 3) idarubicin is not a substrate for ABCG2 and can kill the ABCG2-expressing 6.2 cells.
For Figure 2C 
ABCG2 mRNA expression in AML clones
To measure ABCG2 mRNA expression levels in the AML clones, Northern analysis of cellular RNA was performed. Clone 6.2 had relatively high levels of ABCG2 transcript, while clone 3.3 had much lower levels of ABCG2 mRNA (Fig. 3) . The parental OCI-AML3 cells had no detectable ABCG2 mRNA expression. Using Actin as an internal control to normalize for loading, the level of ABCG2 mRNA in clone 6.2 was 1900% that of clone 3.3, and parental OCI-AML 3 cells had 2.8% the level of clone 3.3.
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The amplification range of the real-time RT-PCR assay was demonstrated to be linear for both the ABCG2 and Actin mRNA signals over a range of six logarithmic dilutions of RNA from clone 6.2 (data not shown). This assay was also able to reliably detect the increased ABCG2 mRNA signal resulting from spiking parental OCI-AML3 cells with clone 6.2 cells at a frequency of one cell in 10,000 (data not shown). 
ABCG2 mRNA expression in normal hematopoietic cell populations
Expression of the murine ortholog of ABCG2 has previously been described in primitive stem cell populations from bone marrow, skeletal muscle, and embryonic stem cells of mice 8 .
Normal human hematopoietic populations have also been shown to express ABCG2 mRNA 9 .
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Because leukemic bone marrow and peripheral blood specimens are likely to contain at least some residual normal cells with ABCG2 expression, we quantified this background level in order to interpret ABCG2 levels in leukemic samples. To define the ABCG2 mRNA expression in normal hematopoietic cells, we analyzed RNA from mononuclear cell preparations of human bone marrow (BM), peripheral blood (PB), and umbilical cord blood (CB) specimens by real-time RT-PCR. ABCG2 mRNA levels were relatively low in bone marrow (1.4 %, ± 0.8 % that of clone 3.3), peripheral blood (1.2 %, ± 0.4 %), and umbilical cord blood (6.4 %, ± 0.9 %) populations ( Figure 5A ). These very low levels are consistent with our recent results showing that expression in murine hematopoietic tissues was relatively restricted to rare repopulating stem cells 8 . ABCG2 mRNA expression in CB was significantly higher than levels in BM (p = 0.015) and PB (p = 0.002), consistent with the known higher stem cell frequency in cord blood 19 .
For personal use only. on . by guest www.bloodjournal.org From Figure 5A To determine the ABCG2 mRNA levels in human hematopoietic cell populations enriched for hematopoietic stem cells, we studied RNA samples from G-CSF mobilized peripheral blood stem cells (PBSC) populations magnetically immunopurified for either CD34 or Ac133 antigen expression (>95 % purity). The mean ABCG2 mRNA level of mobilized PB by realtime RT-PCR was 1.2 % that of clone 3.3 (± 0.1 %). Compared to unsorted PBSC, CD34+
and Ac133+ populations contained significantly higher mean ABCG2 mRNA levels (Fig. 5B) , which were 15.6 % ± 2.7 % (p = 0.002), and 10.3 % ± 3.6 % (p = 0.015), respectively. These results are consistent with enrichment of primitive HSC previously shown to be present in 19, 20 . The low ABCG2 levels relative to clone 3.3 are consistent with the specificity of ABCG2 expression in hematopoietic stem cells and the overall low proportion of stem cells in these immunopurified populations.
Figure 5B The results of ABCG2 mRNA quantification can be divided into three categories: low (lower than normal PB and BM), intermediate (greater than PB and BM but lower or equal to clone 3.3), and high (greater than clone 3.3). 18 % of patients had low ABCG2 mRNA levels, ranging from 0.01 % to 2.0 % of the levels in clone 3.3 (Fig. 6) . 75 % of patients had intermediate ABCG2 mRNA levels (2.1 to 100 % of clone 3.3). Three patients (7 %) had high ABCG2 mRNA levels, ranging from 140 % to 2600 % that seen in clone 3.3. Two of these had ABCG2 mRNA levels exceeding the level in clone 6.2. These high-expressing samples showed no PCR amplification when reverse transcriptase was not included in the reaction, indicating that the high ABCG2 levels were not the result of contamination by DNA. category groupings. Altogether, these results showed that most cases of AML has ABCG2 mRNA levels that were significantly greater than in normal bone marrow or peripheral blood, but rarely approached that associated with our drug resistant 6.2 clone.
ABCG2 protein expression in AML samples by flow cytometry
In order to determine the cellular distribution of ABCG2 expression within AML samples, we analyzed several available AML specimens by flow cytometry after labeling with the 5D3 anti -ABCG2 monoclonal antibody. In many cases, the viability was poor after thawing of these frozen samples, as indicated by propidium iodide staining. In three cases with a sufficient number of viable cells, very small subpopulations of ABCG2 positive cells were identified, which represented 2.6 %, 0.4 %, and 1.8 % of total mononuclear cells for patients 8, 16 , and 38, respectively (Fig. 7) . The ratio of 5D3 to isotype mean fluorescent intensity was 3.7, 1.1, and 4.1 for patients 8, 16, and 38, respectively. These results suggest that the ABCG2 mRNA expression levels detected by real-time RT-PCR were due to minor subpopulations of ABCG2 expressing cells, rather than a homogenous distribution of leukemic cells with very low levels of ABCG2 expression. Figure 7 For personal use only. staining results show that this latter scenario was true in all cases we examined by flow cytometry. In these cases, a small subpopulation of ABCG2 expressing cells were the main source for the ABCG2 mRNA signal detected in the blast cell samples. This suggests that the expression per cell in this small subpopulation was relatively high, and could be above the threshold required for drug resistance. This could be clinically significant with regard to drug resistance if these rare cells were clonogenic leukemic stem cells.
There are several other lines of evidence to suggest that leukemic stem cells could express high levels of ABCG2. Several studies have demonstrated both normal and leukemic cells within the SP fraction of AML bone marrow 14, 15 . Furthermore, the side population is often expanded in leukemic marrow 14 . Because ABCG2 expression is a critical molecular determinant of the SP phenotype in normal stem cells 8 , it is possible that leukemic stem cells also share this molecular phenotype. This idea is consistent with the recent report showing that ABCG2 protein expression was positively correlated with a primitive immunophenotype within AML blasts samples 21 . Such a subpopulation might represent a reservoir of primitive leukemic stem cells with intrinsic drug efflux capacity, and could potentially contribute to subsequent relapse in certain cases. This would be consistent with the recent finding of increased ABCG2 mRNA levels at relapse compared to initial diagnosis 22 .
Recently, idarubicin and mitoxantrone have become increasingly used in the remission induction therapy for AML. To our knowledge, this is the first report to demonstrate the lack 
